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Objectives Our goal was to determine the impact of lean mass index (LMI) and body fat (BF) on survival in patients with
coronary heart disease (CHD).
Background An inverse relationship between obesity and prognosis has been demonstrated (the “obesity paradox”) in CHD,
which has been explained by limitations in the use of body mass index in defining body composition.
Methods We studied 570 consecutive patients with CHD who were referred to cardiac rehabilitation, stratified as Low
(25% in men and 35% in women) and High (25% in men and 35% in women) BF and as Low (18.9
kg/m2 in men and 15.4 kg/m2 in women) and High LMI, and followed for 3 years for survival.
Results Mortality is inversely related to LMI (p  0.0001). Mortality was highest in the Low BF/Low LMI group (15%),
which was significantly higher than in the other 3 groups, and lowest in the High BF/High LMI group (2.2%),
which was significantly lower than in the other 3 groups. In Cox regression analysis as categoric variables, low
LMI (hazard ratio [HR]: 3.1; 95% confidence interval [CI]: 1.3 to 7.1) and low BF (HR: 2.6; 95% CI: 1.1 to 6.4)
predicted higher mortality, and as continuous variables, high BF (HR: 0.91; 95% CI: 0.85 to 0.97) and high LMI
(HR: 0.81; 95% CI: 0.65 to 1.00) predicted lower mortality.
Conclusions In patients with stable CHD, both LMI and BF predict mortality, with mortality particularly high in those with Low
LMI/Low BF and lowest in those with High LMI/High BF. Determination of optimal body composition in primary
and secondary CHD prevention is needed. (J Am Coll Cardiol 2012;60:1374–80) © 2012 by the American Col-
lege of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.037i
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tAlthough obesity is considered a risk factor for most cardio-
vascular (CV) diseases, including coronary heart disease
(CHD) (1,2), many studies of cohorts with established CV
diseases, including heart failure, hypertension, atrial fibrillation,
and CHD, have demonstrated an inverse relationship between
obesity, generally determined by body mass index (BMI), and
subsequent prognosis, which has been termed the “obesity
paradox” (1–4). Although BMI is the most frequently used
method to assess overweightness and obesity, this method has
been criticized because BMI does not always reflect true body
fatness (1–4), which may be better evaluated by assessments of
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accepted May 28, 2012.body fat (BF) and fat-free mass (FFM). However, limited data
are available on the impact of FFM and BF on the prognosis
in patients with established CHD. Therefore, we assessed the
impact of both BF and lean mass index (LMI) on 3-year
mortality in a cohort with stable CHD.
Methods
We reviewed 570 consecutive patients with stable CHD
who were referred to cardiac rehabilitation between January
1, 2000, and July 31, 2005, by dividing patients into Low
(25% in men and 35% in women) and High BF (25%
n men and 35% in women) groups, as previously de-
cribed (2,5–7). Patients also were divided according to
MI into 3 groups on the basis of previously defined 25th
o 75th percentiles for analysis of LMI (8): Low (18.7
g/m2 in men and 14.9 kg/m2 in women), Medium (18.7
o 21 kg/m2 in men and 14.9 to 17.2 kg/m2 in women), and
High (21 kg/m2 in men and 17.2 kg/m2 in women).
Patients were also divided into Low (cutoff 18.9 kg/m2 inen and 15.4 kg/m2 in women) and High (18.9 kg/m2
w
L
B
B
c
p
m
w
c
w
T
h
C
t
r
b
u
t
t
u
a
s
a
B
R
T
t
s
f
v
v
v
H
1375JACC Vol. 60, No. 15, 2012 Lavie et al.
October 9, 2012:1374–80 Lean Mass and Coronary Mortalityin men and 15.4 kg/m2 in women), as previously defined
(9), to be combined with the BF subgroups. Thus, 4 groups
ere analyzed: Low BF/Low LMI (n  62), High BF/Low
MI (n  53), Low BF/High LMI (n  179), and High
F/High LMI (n  276).
aseline assessment. Baseline laboratory parameters, in-
luding BF by the sum of the skin-fold method, was
erformed as described previously (2,5). LMI was deter-
ined by (1-BF)  BMI kg/m2, as previously described
(8,9). We then divided actual body weight minus ideal body
weight proportionally to %BF and used mean LMI for that
gender to establish excess lean mass and excess fat mass. The
prevalence of hypertension, current smoking, diabetes, and
chronic obstructive pulmonary disease (COPD) was also
assessed. Patients were followed for an average of 3 years
(mean 1,266  527 days, median 1,356 days, range 231 to
2,149 days) to determine all-cause mortality assessed by the
National Death Index.
Statistical analysis. SAS version 9.0 (SAS Institute Inc.,
Cary, North Carolina) computer software was used for
statistical analysis. Mean  SD or proportions for baseline
characteristics were reported, and the 3 LMI groups and the 4
BF/LMI groups were compared with analysis of variance and
chi-square analysis. Kaplan-Meier survival curves were con-
structed to assess survival in the LMI subgroups and by both
High/Low BF and High/Low LMI. Cox regression analysis
was performed to predict mortality using age, gender, ejection
fraction (EF), peak oxygen consumption (VO2), BF, and LMI,
ith BF and LMI introduced as categoric (low vs. high) and
ontinuous variables. Because of the possibility of overfitting,
e also performed the Cox regression without age and gender.
his analysis also was performed with 27 patients classified as
Baseline Characteristics of the Study PopulatioTable 1 Baseline Characteristics of the Stu
Population
(n  570)
BMI, kg/m2 28.5 5.1
% BF 29.3 7.7
LMI, kg/m2 19.9 2.7
Age, yrs 64.0 10.6
Systolic BP, mm Hg 125.5 19.3
Diastolic BP, mm Hg 73.7 10.5
EF, % 54.5 11.4
Peak flow O2, ml/kg/min 16.7 5.3
Total cholesterol, mg/dl 167.4 37.5
HDL, mg/dl 41.3 12.8
LDL, mg/dl 97.1 32.9
Triglycerides, mg/dl 149.1 83.3
C-reactive protein, mg/l 5.6 9.2
Fasting glucose, mg/dl 110.3 29.8
% Female subjects 26.8% (153/570)
% Hypertensive subjects 35.8% (188/525)
% Smokers 1.4% (6/435)
% Diabetic subjects 22.7% (55/242)
Values are mean  SD or % (n/N).
BF body fat; BMI body mass index; BP blood pressure; EF ejection f
LMI  lean mass index.aving COPD, as well as with
OPD as a categoric variable in
he multivariate analysis. Logistic
egression analysis was performed,
ut the main results were reported
sing Cox regression because pa-
ients had variable follow-up dura-
ions. Pearson’s correlation was
sed to correlate BF with LMI
nd traditional risk factors. Kappa
tatistic was used to determine the
greement between the LMI and
F groups.
esults
he baseline characteristics of
he study population are de-
cribed in Table 1. During
ollow-up, 26 patients died; sur-
ivors had significantly higher
alues for BMI, BF, LMI, left
entricular EF, and peak VO2, and borderline higher levels
of systolic blood pressure than those who died.
The baseline characteristics of the 3 distinct LMI groups
are described in Table 2, with the groups demonstrating
significant differences in BMI, % BF, age, high-density
lipoprotein (HDL) cholesterol, triglycerides, and gender.
The baseline characteristics of the 4 distinct body compo-
sition groups based on both BF and LMI are shown in
Table 3, with the groups differing in BMI, age, peak VO2,
DL cholesterol, triglycerides, and smoking. All partici-
Abbreviations
and Acronyms
BF  body fat
BMI  body mass index
CHD  coronary heart
disease
CI  confidence interval
COPD  chronic
obstructive pulmonary
disease
CV  cardiovascular
EF  ejection fraction
FFM  fat-free mass
HDL  high-density
lipoprotein
HR  hazard ratio
LMI  lean mass index
OR  odds ratio
VO2  oxygen consumption
pulation
Survivors
(n  544)
Nonsurvivors
(n  26) p Value
28.7 5.1 25.1 5.1 0.0003
29.6 7.9 25.2 6.8 0.0058
20.0 2.8 18.5 2.8 0.008
63.7 10.5 72.1 9.4 0.0001
25.9 19.1 110.0 20.9 0.045
73.8 10.5 68.3 13.5 NS
55.0 10.8 42.9 16.7 0.0001
16.9 5.3 12.4 3.3 0.0001
67.3 37.8 171.5 30.0 NS
41.3 12.6 42.9 16.1 NS
97.2 33.3 97.4 25.0 NS
48.7 83.3 155.5 83.7 NS
5.5 9.3 6.5 7.0 NS
10.1 29.9 113.9 26.2 NS
.8% (146/544) 26.9% (7/26) NS
.0% (176/503) 54.6% (12/22) NS
.0% (49/223) 31.6% (6/19) NS
.2% (5/415) 5.0% (1/20) NSraction; HDL high-density lipoprotein; LDL low-densityndy Po
1
1
1
1
26
35
22
1lipoprotein;
B
o
(
w
i
i
w
B
k
I
f
H
b
g
g
c
n
a
h
(
i
T
a
0
H
1
9
T
0
C
(
C
m
S
l
(
B
g
g
L
M
y
[
C
m
le 1.
1376 Lavie et al. JACC Vol. 60, No. 15, 2012
Lean Mass and Coronary Mortality October 9, 2012:1374–80pants in the High BF/High LMI group were considered
overweight (39.5%) or obese (60.5%) by BMI criteria, with
an average BMI of 31.9 kg/m2 for this group. In the Low
F/High LMI group, the majority of participants were
verweight (57.5%), followed by normal (31.3%) and obese
11.1%) by BMI criteria. The High BF/Low LMI group
as approximately evenly divided between overweight partic-
pants (50.9%) and normal participants (43.4%), with a minor-
ty of obese participants (5.7%) by BMI criteria. LMI and BF
ere independent of each other (r  0.07; p  0.07). The
F and LMI groups correlated weakly (r 0.19; p 0.0001;
appa 0.10; 95% confidence interval [CI]: 0.03 to 0.17).
nfluence of body composition on traditional CHD risk
actors. Low HDL cholesterol was associated more with
igh LMI (odds ratio [OR]: 1.46; 95% CI: 1.09 to 1.97),
ut not BF (1.15 95% CI: 0.86 to 1.54), after adjusting for
ender, age, lipid medication use, and impaired fasting
lucose. High low-density lipoprotein cholesterol was asso-
iated with high BF (OR: 1.36; 95% CI: 1.02 to 1.82), but
ot high LMI (OR: 1.02; 95% CI: 0.74 to 1.43), after
djusting for age, gender, and lipid medication use. Both
igh LMI (OR: 1.39; 95% CI: 1.08 to 1.80) and high BF
OR: 1.46; 95% CI: 1.02 to 2.09) were associated with
mpaired fasting glucose after adjusting for age and gender.
he triglyceride/HDL ratio correlated more, although rel-
tively weakly, with the High LMI group (r  0.16; p 
.0001) than with the High BF group (r  0.09; p  0.05).
ypertension was associated more with high LMI (OR:
Baseline Characteristics of the Study Population Divided by LMITable 2 Baseline Characteristics of the Study Population Divid
Low LMI (L) Medium LMI (M
(n  97) (n  216)
BMI, kg/m2 23.4 3.0 26.3 2.5
% BF 26.0 8.0 28.5 7.1
LMI, kg/m2 17.3 1.3 18.7 1.8
Age, yrs 68.0 9.3 66.0 10.5
Systolic BP, mm Hg 121.8 15.0 128.6 19.1
Diastolic BP, mm Hg 72.1 8.3 74.3 10.6
EF, % 54.7 10.7 53.9 11.1
Peak flow O2, ml/kg/min 17.1 5.4 16.8 5.2
Total cholesterol, mg/dl 164.1 33.6 166.6 40.1
HDL, mg/dl 43.9 14.8 42.8 12.8
LDL, mg/dl 95.0 25.3 95.8 32.5
Triglycerides, mg/dl 127.3 80.9 141.1 71.0
C-reactive protein, mg/l 5.8 14.5 5.2 7.1
Fasting glucose, mg/dl 104.4 19.8 109.9 32.7
% Hypertensive subjects 31.4% (27/86) 34.3% (68/198
% Female subjects 12.3% (12/97) 28.2% (61/216
% Smokers 3.0% (2/67) 1.2% (21/168
% Diabetic subjects 19.1% (8/42) 17.1% (15/88)
Values are mean  SD or % (n/N).
ANOVA  analysis of variance; H  high; L  low; M  medium; other abbreviations as in Tab.31; 95% CI: 1.0 to 1.69) than with high BF (OR: 1.18; 95% CI: 0.82 to 1.69) after adjusting for age and gender.
riglycerides correlated weakly with BF (r  0.09; p 
.04) and high LMI (r  0.16; p  0.0001). High
-reactive protein was not significantly associated with BF
OR: 1.36; 95% CI: 0.83 to 2.20) or LMI (OR: 1.41; 95%
I: 0.99 to 2.01) after adjusting for age, gender, and lipid
edication use.
urvival curves. In Figure 1, mortality was inversely re-
ated with LMI, which was highest in the Low LMI group
10.3% [10 of 97]; p 0.0001 vs. the High LMI; p 0.003
vs. the Medium LMI) and lowest in the High LMI group
(2.7% [7 of 257]). Intermediate mortality was noted in the
Medium LMI group (4.2% [9 of 216]; p  0.2 compared
with the High LMI group).
As shown in Figure 2, mortality was highest in the Low
BF/Low LMI group (15% [9 of 62]), which was signifi-
cantly higher than in the other 3 groups (4.5% [8 of 179] for
Low BF/High LMI, p  0.001; 5.7% [3 of 53] for High
BF/Low LMI, p  0.0025; and 2.2% [6 of 270] for High
F/High LMI, p  0.0001). The High BF/High LMI
roup had significantly lower mortality than all of the
roups (p  0.003 vs. High BF/Low LMI; p  0.03 vs.
ow BF/High LMI).
ultivariate predictors of mortality. In multivariate anal-
sis using Cox regression (Table 4), low LMI (hazard ratio
HR]: 3.1; 95% CI: 1.3 to 7.1) and low BF (HR: 2.6; 95%
I: 1.1 to 6.4) as categoric variables predicted higher
ortality, and as continuous variables, high BF (HR: 0.91;
LMI
LMI Groups
High LMI (H)
ANOVA (p Value)(n  257)
32.4 4.6 0.0001
31.4 8.0 0.0001
22.0 2.3 0.0001
60.9 10.3 0.0001
124.2 20.3 NS
73.6 11.1 NS
54.9 11.9 NS
16.5 5.2 NS
169.4 36.5 NS
39.2 11.6 0.001
99.1 35.7 NS
163.7 90.9 0.001
5.9 8.2 NS
112.7 29.9 NS
Chi-Square (p Value)
L – M M – H L – H
38.6% (93/251) NS NS NS
31.1% (80/257) 0.002 NS 0.0003
1.0% (2/200) NS NS NS
28.6% (32/112) NS NS NSed by
)
)
)
)5% CI: 0.85 to 0.97) and high LMI (HR: 0.81; 95% CI:
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October 9, 2012:1374–80 Lean Mass and Coronary Mortality0.65 to 1.00) predicted lower mortality. If only peak VO2
and EF were entered into the Cox regression with BF and
LMI, both LMI and BF as categoric variables remained
significant predictors of mortality, as did BF as a continuous
variable, but LMI as a continuous variable was not a
significant predictor (HR: 0.86; 95% CI: 0.73 to 1.02).
Other independent predictors of 3-year mortality included
peak VO2 and EF. Although higher age was associated with
trend for worse survival, this was not statistically signifi-
ant. Gender also was not significantly associated with
urvival. By using logistic regression, high BF (OR: 0.90;
5% CI: 0.84 to 0.97) and high LMI (OR: 0.75; 95% CI:
.58 to 0.97) as continuous variables were independent
redictors of lower mortality, and as categoric variables, low
F (OR: 3.3; CI: 1.2 to 9.0) and low LMI (OR: 3.7; 95%
I: 1.4 to 9.8) were independent predictors of higher
ortality. In addition, surplus lean mass (OR: 0.90; 95%
I: 0.84 to 0.97) and fat mass (OR: 0.92; 95% CI: 0.86 to
.99) both independently predicted lower mortality. There
as no significant interaction between BF and LMI in any
f the subgroups.
nfluence of COPD. In our cohort, 567 patients coded yes
Baseline Characteristics of the Study Population Divided by BF andTable 3 Baseline Characteristics of the Study Population Divid
4 LMI -
Low % BF Low LMI
(LBF LLMI)
Low % BF High
(LBF HLMI)
(n  62) (n  179)
BMI, kg/m2 22.0 2.0 26.6 3.1
% BF 22.1 4.8 24.0 4.9
LMI, kg/m2 17.1 1.5 20.2 2.5
Age, yrs 69.2 9.2 63.3 11.
Systolic BP, mm Hg 120.5 16.0 126.5 20.
Diastolic BP, mm Hg 70.0 6.4 73.4 10.
EF, % 54.2 11.6 53.0 12.
Peak flow O2, ml/kg/min 16.8 4.5 17.5 5.5
Total cholesterol, mg/dl 167.5 36.1 166.6 40.
HDL, mg/dl 46.2 15.6 41.5 14.
LDL, mg/dl 96.9 26.0 95.8 31.
Triglycerides, mg/dl 119.7 55.4 147.5 75.
C-reactive protein, mg/L 6.1 14.9 4.5 6.5
Fasting glucose, mg/dl 102.3 15.5 107.2 25.
Catego
% Hypertensive subjects 38.2% (21/55) 36.8% (60/16
% Female subjects 21.0% (13/62) 29.6% (53/17
% Smokers 4.8% (2/42) 1.6% (2/128
% Diabetic subjects 12.9% (4/31) 22.0% (18/82
Comparison of
LBF LLMI – LBF HLMI LBF LLMI – HBF LLMI LBF LLMI – HBF HLMI
NS NS NS
NS NS NS
NS 0.0001 NS
NS NS NS
Values are mean  SD or % (n/N).
HBF  high body fat; HLMI  high lean mass index; LBF  low body fat; LLMI  low lean masr no for COPD; mortality was markedly higher (18.5%) in lhose coded yes for COPD versus only 3.9% in those coded
o for COPD (p  0.004) (Table 5). Compared with those
ithout COPD, those with COPD had lower BMI, LMI,
eak VO2, and fasting glucose; a lower prevalence of
iabetes; higher age, total cholesterol, HDL-cholesterol,
nd low-density lipoprotein cholesterol; and a higher prev-
lence of female subjects and smokers with a trend of lower
F (which was not statistically significant).
However, when COPD was entered into the Cox regres-
ion analysis, COPD was not a significant independent
redictor of mortality (HR: 0.65; 95% CI: 0.18 to 2.32) and
id not have a major effect on the impact of BF (HR: 0.91;
5% CI: 0.85 to 0.97) as an independent predictor of
ortality, but it modestly weakened LMI (HR: 0.96; 95%
I: 0.85 to 1.08).
nfluence of gender. When stratifying the population by
ender, we found similar results. For women, when entered
ndividually, BF and LMI were independently associated
ith lower mortality (BF HR: 0.84; 95% CI: 0.74 to 0.95
nd LMI HR: 0.36; 95% CI: 0.15 to 0.86). However, when
ombined, BF (HR: 0.87; 95% CI: 0.76 to 0.99), but not
MI (HR: 0.49; 95% CI: 0.21 to 1.14), was associated with
BF and LMI
Groups
High % BF Low LMI
(HBF LLMI)
High % BF High LMI
(HBF HLMI) ANOVA
p < 0.05(n  53) (n  276)
25.5 3.0 31.9 4.5 0.0001
32.6 8.1 33.9 6.6 0.0001
17.2 1.3 20.9 2.6 0.0001
66.2 9.2 63.0 10.0 0.0001
124.9 17.1 125.9 19.2 NS
74.5 9.9 74.2 11.1 NS
54.3 11.6 55.5 10.5 NS
16.7 6.0 16.1 5.1 0.04
164.4 31.2 168.5 37.4 NS
43.2 13.4 39.8 10.7 0.004
93.9 25.9 98.7 36.5 NS
140.1 98.3 158.0 88.4 0.01
4.7 11.4 6.4 8.4 NS
109.5 27.2 114.1 34.2 0.02
riables
31.3% (15/48) 35.5% (92/259)
18.9% (10/53) 27.9% (77/276)
0.0% (0/38) 0.9% (2/227)
31.6% (6/19) 24.6% (27/110)
oric Variables
LBF HLMI – LBF HLMI LBF HLMI – HBF HLMI HBF LLMI – HBF HLMI
NS NS NS
NS NS NS
0.0001 NS 0.0001
NS NS NS
other abbreviations as in Tables 1 and 2.LMIed by
% BF
LMI
7
9
4
5
0
1
0
2
6
ric Va
3)
9)
)
)
Categower mortality. For men, BF and LMI were associated
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Lean Mass and Coronary Mortality October 9, 2012:1374–80with a trend toward lower mortality, both when entered
individually (BF HR: 0.94; CI: 0.86 to 1.02 and LMI HR:
0.85; 95% CI: 0.70 to 1.04) and together (BF HR: 0.94;
95% CI: 0.87 to 1.02 and LMI HR: 0.85; 95% CI: 0.68 to
1.06).
Discussion
We demonstrated that mortality seems to be inversely related
with LMI in patients with stable CHD. Mortality is highest in
patients with Low BF/Low LMI, lowest in those with High
BF/High LMI, and intermediate in those with High BF/Low
LMI or Low BF/High LMI. Both Low LMI and Low BF as
Figure 1 Kaplan-Meier Survival Curve for Different Levels of Lea
Mortality was inversely related with LMI: 10.3% in the Low LMI group (10 of 97), 4
LMI  lean mass index.
Figure 2 3-Year Survival Based on Body Composition: Low and
Mortality was highest in the Low BF/Low LMI group (15% or 9 of 62), followed by
Low BF/High LMI group (4.5% or 8 of 179), and High BF/High LMI group (2.2% orcategoric variables were independent predictors of an approx-
imately 3-fold higher mortality.
Obesity paradox in CHD. Despite the powerful associa-
tion of overweightness and obesity with CHD risk factors and
CHD, numerous studies have reported that in those with estab-
lished CHD, patients who are overweight and obese have a better
clinical prognosis than their lean counterparts with similar CHD,
a process that has been termed the “obesity paradox” (1–4), which
has been demonstrated in many CHD cohorts (1–5). Although
most studies on the obesity paradox used BMI, we have demon-
strated that BF also is inversely associated with mortality in
patients with CHD (2,5), a fact that is confirmed in the present
ss Index
the Medium LMI group (9 of 216), and 2.7% in the High LMI group (7 of 257).
Body Fat and Low and High Lean Mass Index
h BF/Low LMI group (5.7% or 3 of 53),
70). BF  body fat; LMI  lean mass index.n Ma
.2% inHigh
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October 9, 2012:1374–80 Lean Mass and Coronary Mortalitystudy, with low BF being an independent predictor of an approx-
imately 3-fold higher mortality in patients with CHD. Of note,
these data showed the powerful association of high BF with better
survival despite the fact that higher BF was associated with a worse
overall CHD risk profile.
One limitation of previous studies assessing the obesity
paradox is that FFM or LMI was not accounted for. In our
study, we estimated LMI by determination of BF and defined
LMI as the BMI that was not accounted for by fat. To our
knowledge, this assessment has not been performed in the
assessment of patients with CHD and the obesity paradox. We
found that unlike BF, which was associated with an obesity
paradox in that higher BF was associated with lower mortality,
patients with CHD with higher LMI, as would be suggested
from the epidemiologic studies, also had a better prognosis. In
fact, the best prognosis was noted in those patients with High
BF/High LMI, and the highest mortality was noted in those
with Low BF/Low LMI. In the multivariate analysis, low
LMI as a categoric variable was an independent predictor of a
more than 3-fold higher mortality, whereas as a continuous
variable, higher LMI was at least strongly associated with
better survival. As discussed earlier for BF, a higher LMI also
was associated with a worse overall CHD risk profile, so a
more favorable impact of LMI with CHD risk factors does not
explain the protective effect of higher LMI in a CHD cohort.
As in most other analyses, our study is not able to control for
nonpurposeful weight loss before study entry. However, in pa-
tients who are referred to cardiac rehabilitation programs, other
medical problems are generally stable. Others have suggested that
the obesity paradox may be modified by overall physical wellness
or by unmeasured confounding factors (10). High levels of fitness
significantly alter the association of BMI and other parameters for
obesity with subsequent mortality (11–13). Our data were ad-
justed for fitness, and still BF and LMI were independent
predictors of mortality. In addition, only 6 of 570 patients were
Cox Regression Model for Mortality UsingBF and LMI as Categoric and Con inuous VariablesTable 4 Cox R ressio Model for Mortality U ingBF and LMI as Categoric and Continuous Variables
HR 95% CI HR 95% CI
Parameter
With BF and LMI as
Categoric Variables
(Low vs. High)
With BF and LMI as
Continuous
Variables
BF 2.6 1.1–6.4 0.91 0.85–0.97
LMI 3.1 1.3–7.1 0.81 0.65–1.00
LVEF 0.96 0.93–0.98 0.96 0.93–0.98
Peak VO2 0.78 0.69–0.89 0.78 0.68–0.89
Age 1.03 0.98–1.09 1.01 0.96–1.07
Gender (female vs. male) 0.53 0.19–1.53 0.96 0.13–1.65
BF 2.6 1.1–6.1 0.89 0.84–0.95
LMI 3.9 1.7–8.7 0.86 0.73–1.02
LVEF 0.95 0.93–0.98 0.79 0.70–0.88
Peak VO2 0.79 0.71–0.88 0.96 0.93–0.98
The bottom or unshaded portion of the table contains the Cox Regression Model without including
age and gender, which are contained in the top or shaded portion of the table.
CI  confidence interval; HR  hazard ratio; LVEF  left ventricular ejection fraction; VO2 
oxygen consumption; other abbreviations as in Table 1.“underweight” (BMI18.5 kg/m2), although these patients had T0% mortality; eliminating these patients did not significantly alter
ny of the major conclusions. Few of our patients were active
mokers, and many studies of CHD cohorts have demonstrated
hat smoking cessation in CHD is associated with a favorable
rognosis, nearly equal to never smokers within approximately 6
onths of smoking cessation (14). In a large meta-analysis of
00,000 subjects, Whitlock et al. (15) observed an inverse rela-
ionship of BMI with mortality at a BMI of 22.5 kg/m2,
ttributed to respiratory disease, but this was not an independent
redictor of mortality in our multivariate analysis. In addition,
ncluding COPD in our multivariable model did not change the
nfluence of BF on mortality risk, although it weakened the
elationship of LMI. Even in patients with peripheral arterial
isease, in whom smoking and COPD are prevalent and strongly
ssociated with this disease, COPD did not completely explain
he obesity paradox (14,16). A recent study of more than 50,000
atients with ST-segment elevation myocardial infarction
howed that the highest in-hospital mortality was in the
normal” BMI group, followed closely by the class 3 obese or
everely obese patients. However, after correcting for baseline
actors, mortality was increased only in the severely obese
roup, suggesting that confounding factors explained the
igher mortality in the lower BMI groups (17,18). Neverthe-
ess, this study assessed only in-hospital mortality, and so far
onfounders have not totally explained the obesity paradox
17–19).
It is interesting to speculate that although high BF may
e a risk factor for CV diseases and CHD, by some
echanism this may be protective in cohorts with known
isease. For example, before a CV event, positive caloric
alance leading to adiposity may result in pathogenic adipose
Impact of COPD on Mortality in the Coronary CohortTable 5 Impact of COPD on Mortality in the Coronary Cohort
Non-COPD
(n  540)
COPD
(n  27) p Value
BMI, kg/m2 28.7 5.1 25.4 5.2 0.001
% BF 29.5 7.9 27.3 9.0 NS
LMI, kg/m2 20.0 2.8 18.1 2.5 0.0005
Age, yrs 63.7 10.6 71.6 6.4 0.0001
Systolic BP, mm Hg 125.6 19.4 124.0 5.3 NS
Diastolic BP, mm Hg 73.7 10.6 72.0 7.2 NS
EF, % 54.5 11.4 55.3 9.0 NS
Peak flow O2, ml/kg/min 16.9 5.2 11.8 3.1 0.0001
Total cholesterol, mg/dl 166.1 37.0 200.7 37.5 0.0001
HDL, mg/dl 40.5 11.5 63.1 22.8 0.0001
LDL, mg/dl 96.5 32.8 112.5 34.6 0.029
Triglycerides, mg/dl 150.0 84.0 125.7 60.3 NS
C-reactive protein, mg/l 5.6 9.3 4.1 4.8 NS
Fasting glucose, mg/dl 110.9 30.1 96.2 10.3 0.03
% Female subjects 25.6% (138/540) 51.9% (14/27) 0.003
% Smokers 34.4% (171/497) 65.4% (17/26) 0.001
% Hypertensive subjects 1.2% (5/407) 3.9% (1/26) NS
% Diabetic subjects 25.2% (55/218) 0% (0/24) 0.005
% Mortality 3.9% (21/540) 18.5% (5/27) 0.0004
Values are mean  SD or % (n/N).
COPD chronic obstructive pulmonary disease; EF ejection fraction; other abbreviations as in
able 1.
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risk. Paradoxically, during a time of negative caloric balance, as
may occur during a CV event or major interventional proce-
dure, adipose tissue may respond with enhanced function,
which may improve CV and other clinical outcomes (5,20).
Another interesting possibility is that higher BF and especially
higher LMI may be associated with muscular strength, which
is associated with better prognosis (21,22) and survival
in several populations, even independently of aerobic fitness.
Study limitations. This is a relatively small, retrospective
study of a select cohort, and the follow-up was relatively
short. We assessed BF by the sum of the skin-fold method,
which has potential limitations. We calculated LMI on the
basis of the assessment of BF; the cut-points used for LMI
have been validated (8,9), but not using the skin-fold
assessment; also, because we estimated subcutaneous BF,
visceral BF may be included in our LMI. Although we
measured body composition, we did not measure BF and
lean mass distribution; 2 recent studies (both including
Mayo Clinic data) demonstrated that central obesity was
associated with mortality in CHD (12,23), whereas a study
in heart failure indicated that central obesity was associated
with better survival (24,25). Although we corrected for
COPD, our study did not use assessment of pulmonary
function. In addition, we assessed total mortality (which may
be the most important and reliable end point), but we did not
assess other CHD morbidity. Finally, because our study was
small and several variables were used in the Cox regression
analysis, a potential limitation is that overfitted models may
capitalize on the idiosyncrasies of the sample at hand. How-
ever, even when limiting the variables studied in the Cox
regression analysis, both LMI and BF as categoric variables
and BF as a continuous variable remained significant predictors
of mortality, whereas LMI as a continuous variable became a
borderline significant predictor.
Conclusions
Despite the recognized study limitations, our findings indicate
that both high LMI and high BF are independent predictors of
better survival in those with stable CHD, with mortality
especially high in the Low BF/Low LMI group and lowest in
the High BF/High LMI group. Prospective studies are needed
to validate our findings and to determine the optimal body
composition in both primary and secondary CHD prevention.
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